Main Article Content
Background. The result of surgical treatment of goiter with severe thyrotoxicosis may be an improvement in general condition and physical activity, a decrease and/or elimination of clinical manifestations of thyrotoxic cardiomyopathy (effective treatment), or a worsening of the general condition (ineffective treatment). From the standpoint of such approach, the longterm results of surgical treatment of toxic goiter with severe thyrotoxicosis have not been sufficiently studied. The purpose was to investigate the longterm effects of surgical treatment of patients with toxic goiter and severe thyrotoxicosis with a priority study of changes in cardiac activity and physical activity. Materials and methods. Studies have been carried out in 123 surgically treated patients with severe toxic goiter. Patients’ age ranged from 21 to 74 years. The duration of thyrotoxicosis was from 18 to 74 months. Indications for surgical treatment were frequent relapses of thyrotoxicosis, progression of thyrotoxic cardiomyopathy against the background of thyrostatic therapy with the development of heart rhythm disorders and heart failure. Structural and functional changes in the heart according to Bmode echocardiography, cardiac disorders according to the results of daily Holter monitoring, physical activity according to a sixminute walk test have been studied. Longterm effects of treatment have been evaluated by gradation developed by us: good, satisfactory, unsatisfactory result and ineffective treatment. Results. It has been found that the surgical treatment of patients with toxic goiter and severe thyrotoxicosis allows eliminating thyrotoxicosis and in some patients — heart rhythm disorders, reducing the severity of clinical manifestations of thyrotoxic cardiomyopathy, improving physical activity and general condition. Studies have shown that the results of surgical treatment depended on the severity of heart rhythm disorders and heart failure, i.e. the effects of thyrotoxicosis, which develop against the background of thyrotoxic cardiomyopathy. Good and satisfactory results of surgical treatment have been obtained in 55 (44.7 %) cases, unsatisfactory results — in 40 (32.5 %) patients, and the treatment was ineffective in 28 (22.8 %) persons. Conclusions. Surgical treatment of patients with toxic goiter and severe thyrotoxicosis helps achieve positive results: to eliminate thyrotoxicosis, reduce the severity of clinical manifestations of thyrotoxic cardiomyopathy, improve cardiac activity, physical activity and general condition of patients. The longterm results of surgical treatment of patients with severe thyrotoxicosis depend on the duration of the disease, drug therapy of thyrotoxicosis and the age of the patients. With an increase in these values, treatment results deteriorate. Among existing indications for the surgical treatment of patients with toxic goiter and manifestations of severe thyrotoxicosis, the first and most important one is the presence of thyrotoxic cardiomyopathy with heart rhythm disorders. The universal indicator for predicting longterm results of surgical treatment of patients with toxic goiter is the distance covered during a sixminute walk test.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Aristarkhov VG, Kvasov AV, Donyukov AI, Aristarkhov RV, Biryukov SV, Pusin DA. Comparative long-term results of surgical treatment of patients with diffuse toxic goiter. Khirurgiya. Zhurnal imeni NI Pirogova. 2017;(8):13-17. doi: 10.17116/hirurgia2017813-17. (in Russian).
Babenko AYu, Grineva EN, Solncev VN. Determinants of development and preservation of atrial fibrillation at thyrotoxicosis. Klinicheskaia I eksperimentalnaia tiroidologia. 2013;9(1):29-37. (in Russian).
Skvortsov VV, Fomina NG, Emel'ianov DN. Current aspects of pharmacotherapy of heart failure in patients with thyrotoxic myocardial dystrophy (cardiopathy). Lekarstvennyj vestnik. 2014;8(55):39-47. (in Russian).
Kravtsiv VV, Shidlovskyi VO, Shidlovskyi OV. Thyrotoxic Cardiomyopathy and Heart Failure in Patients with Toxic Goiter. Changes after Surgery. Galician Medical Journal. 2016;23(3):31-33. doi: 10.21802/gmj.2016.3.4. (in Ukrainian).
Brandt F, Thvilum М, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013 Jun 20;8(6):e66711. doi: 10.1371/journal.pone.0066711.
Brandt F1, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011 Oct;165(4):491-7. doi: 10.1530/EJE-11-0299.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
Kovalenko VM, Sychov OS, DolzhenkoMM, Ivaniv JuA, Dejak SI, Potashev SV. Quantitative echocardiographic evaluation of heart cavities: Guidelines of the working group on functional diagnostics of the Association of Cardiologists of Ukraine and the All-Ukrainian Association of Specialists in Echocardiography. Available from: http://www.webcardio.org/kiljkisna-ekhokardioghrafichna-otsinka-porozhnyn-sertsya.aspx. Accessed: October 19, 2016. (in Ukrainian).
Voronkov LG, Amosova KM, Bagriy AE, Dziak GV, et al. Guidelines of the Ukrainian Association of Cardiology of the diagnosis, treatment and prevention of chronic heart failure in adults (short version). East European Journal of Internal and Family Medicine. 2015;(1):65-71. doi: 10.15407/internalmed2015.01.065. (in Ukrainian).
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128.